Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A randomized phase III trial of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG intergroup study (HECTOR).
Jalid Sehouli
No relevant relationships to disclose
Werner Meier
No relevant relationships to disclose
Pauline Wimberger
No relevant relationships to disclose
Radoslav Chekerov
No relevant relationships to disclose
Antje Belau
No relevant relationships to disclose
Sven Mahner
No relevant relationships to disclose
Christian Kurzeder
No relevant relationships to disclose
Felix Hilpert
No relevant relationships to disclose
Peter Klare
No relevant relationships to disclose
Steffen Doerfel
No relevant relationships to disclose
Hans-Georg Strauss
No relevant relationships to disclose
Ulrich Canzler
No relevant relationships to disclose
Christian Marth
No relevant relationships to disclose
Alexander Reinthaller
No relevant relationships to disclose
Edgar Petru
No relevant relationships to disclose
Rolf Richter
No relevant relationships to disclose
Maria Jesus Rubio
No relevant relationships to disclose
Isabel Bover
No relevant relationships to disclose
Antonio Gonzalez-Martin
No relevant relationships to disclose
Philipp Harter
No relevant relationships to disclose